Edition:
India

Solasia Pharma KK (4597.T)

4597.T on Tokyo Stock Exchange

306JPY
22 Jun 2018
Change (% chg)

¥-2 (-0.65%)
Prev Close
¥308
Open
¥306
Day's High
¥309
Day's Low
¥304
Volume
651,300
Avg. Vol
2,065,138
52-wk High
¥510
52-wk Low
¥287

Latest Key Developments (Source: Significant Developments)

Pledpharma and Solasia enter license agreement on Pledox in Asia
Monday, 20 Nov 2017 

Nov 20 (Reuters) - PLEDPHARMA AB (PUBL) :PLEDPHARMA AND SOLASIA ENTER LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE PLEDOX® IN ASIA .PLEDPHARMA AB (PUBL) - ‍SOLASIA WILL PAY UPFRONT, DEVELOPMENT, REGULATORY AND SALES MILESTONES OF UP TO ABOUT USD 83 MILLION​.PLEDPHARMA AB (PUBL) - ‍SOLASIA WILL PAY INDUSTRY STANDARD ROYALTY RATES ON SALES​.PLEDPHARMA AB (PUBL) - ‍WILL ALSO FULLY FINANCE AN EXPANSION OF PHASE III PROGRAM FOR PLEDOX​.‍TOTAL VALUE OF UPFRONT AND MILESTONE PAYMENTS IS UP TO JPY 9.3 BILLION​.‍PHASE III STUDIES ANTICIPATED TO BE INITIATED END OF 2017 WITH TOP LINE RESULTS EXPECTED IN 2020​.  Full Article

BRIEF-Solasia Pharma says termination of clinical trials phase 1 of SP-04

* Says it announces termination of SP-04 clinical trials phase 1, for treatment of peripheral nerves disability